10x Genomics, Inc.
TXG- Exchange
- Nasdaq
- Industry
- Laboratory Analytical Instruments
- SEC CIK
- 0001770787
In the last 90 days, 10x Genomics, Inc. insiders filed 0 open-market purchases and 11 sales; 393 institutions reported holding it in 13F filings for Q2 2026, worth $4.92B in total; superinvestors ARK Invest and Duquesne Family Office hold it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by 10x Genomics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 11 filings
- 6 insiders, $12.2M in total
- Insiders trading
- 6
- Net value
- −$12.2M
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for 10x Genomics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Suliman Shehnaaz | Director | 23,792 | Sep 24, 2026 | 4 |
| Saxonov Serge | Chief Executive Officer | 1,050,249 | Sep 24, 2026 | 14 |
| Taich Adam | Chief Financial Officer | 316,344 | Sep 11, 2026 | 6 |
| Stuelpnagel John R | Director | 328,436 | Sep 8, 2026 | 3 |
| Hindson Benjamin J. | See Remarks | 488,182 | Aug 26, 2026 | 5 |
| Teichmann Sarah A. | Director | 28,058 | Aug 17, 2026 | 3 |
| Popovits Kimberly J | Director | 37,445 | Jun 8, 2026 | 1 |
| Mateo Alan | Director | 85,877 | Jun 8, 2026 | 1 |
| Kosaraju Sridhar | Director | 65,278 | Jun 8, 2026 | 1 |
| McAnear Justin J. | Other: Former Chief Financial Officer | 143,242 | Aug 26, 2024 | 0 |
| Mammen Mathai | Director | 180,259 | Jun 13, 2024 | 0 |
| Wilbur James | Chief Commercial Officer | 83,342 | Nov 27, 2023 | 0 |
| Roberts Bryan E | Director | 88,503 | Jun 16, 2023 | 0 |
| Crutchfield Bradford | Other: former officer | 97,237 | Aug 25, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 8, 2026 (view filing)7:00 PM ET | Sep 3 | 5 days | Stuelpnagel John RDirector | SSaleClass A Common Stock | −20.0K | $61.75 | −$1.24M | −5.7%328.4K after | 3 lots |
| Sep 11, 2026 (view filing)4:47 PM ET | Sep 9 | 2 days | Taich AdamChief Financial Officer | SSaleClass A Common Stock | −46.4K | $64.57 | −$3.00M | −12.8%316.3K after | 3 lots10b5-1 |
| Sep 24, 2026 (view filing)4:29 PM ET | Sep 22 | 2 days | Saxonov SergeChief Executive Officer | SSaleClass A Common Stock | −25.0K | $81.22 | −$2.03M | −2.3%1.05M after | 5 lots10b5-1 |
| Sep 24, 2026 (view filing)4:30 PM ET | Sep 22 | 2 days | Suliman ShehnaazDirector | SSaleClass A Common Stock | −5.72K | $81.19 | −$464.7K | −19.4%23.8K after | 5 lots10b5-1 |